A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

Clinical trial NCT05788536 · RECRUITING

Trial details

NCT number: NCT05788536
Sponsor: Regeneron Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Start date: 2023-06-27
Primary completion: 2029-02-26
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.